![](https://voice.ons.org//sites/default/files/2024-07/woman-taking-medication-800.jpg)
Gender-Affirming Hormones May Lower PSA and Delay Prostate Cancer Diagnosis in Transgender Women
Median prostate-specific antigen (PSA) levels are lower in transgender women receiving estrogen than comparable cisgender men without a prostate cancer diagnosis, researchers reported in study findings published in JAMA, possibly because of the gender-affirming therapy’s castrating effects. The finding raises questions about the utility of PSA testing for transgender women with intact prostates.